Encore Medical
This article was originally published in The Gray Sheet
Executive Summary
Receives FDA go ahead to begin product development protocol for ceramic-on-ceramic hip implant. One thousand patients at 13 U.S. sites will be enrolled in two studies involving both a cementless and a hybrid (cemented stem/cementless acetabular component) version of the implant, which will be compared to a ceramic/polyethylene acetabular insert. Enrollment is expected to take 12-18 months, followed by a two-year follow-up period
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.